A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors Clinical Trial

Official title:

A Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04381650
• Other study ID #: TAK-981-1502
• Secondary ID: 2020-004325-23jR
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: August 17, 2020
• Est. completion date: November 30, 2025

Study information

• Verified date: March 2024
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

TAK-981 is being tested in combination with pembrolizumab to treat participants who have select advanced or metastatic solid tumors. The study aims are to evaluate the safety, tolerability, and preliminary efficacy of TAK-981 in combination with pembrolizumab. Participants will be on this combination treatment for 21-day cycles. They will continue with this treatment for up to 24 months or until participants meet any discontinuation criteria.

Description:

The drug being tested in this study is called TAK-981. TAK-981 is being tested to treat people who have select advanced or metastatic solid tumors. The study will include a dose escalation phase and a dose expansion phase. The study will enroll approximately 231 participants, approximately 32 participants in the dose escalation phase 1 and approximately 76 to 199 participants in the 8 cohorts of dose expansion phase 2. Participants will receive escalating doses of TAK-981 and fixed dose of pembrolizumab until recommended phase 2 dose (RP2D) is determined: • Dose Escalation: TAK-981 + Pembrolizumab (Fixed Dose) Once Phase 2 doses are identified, participants of select advanced or metastatic solid tumors will receive TAK-981 in below defined cohorts in the expansion phase 2: - Dose Expansion Phase: Cohort A: Non-squamous Non-small Cell Lung Cancer (NSCLC) - Dose Expansion Phase: Cohort B: Cervical Cancer - Dose Expansion Phase: Cohort C: Microsatellite Stable Colorectal Cancer (MSS-CRC) - Dose Expansion Phase: Cohort D: Cutaneous Melanoma - Dose Expansion Phase: Cohort E: Squamous NSCLC - Dose Expansion Phase: Cohort F: Checkpoint Inhibitors (CPI) Refractory Squamous or Nonsquamous NSCLC This multi-center trial will be conducted worldwide. The overall time to participate in this study is 60 months. Participants will make multiple visits to the clinic, and progression-free survival follow-up for maximum up to 12 months after last dose of study drug.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 49
• Est. completion date: November 30, 2025
• Est. primary completion date: November 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Has a histologically or cytologically documented, advanced (metastatic and/or unresectable) cancer as listed below that is incurable: Note: Prior neoadjuvant or adjuvant therapy included in initial treatment may not be considered first- or later-line standard of care treatment unless such treatments were completed less than 12 months prior to the current tumor recurrence. A. Non-squamous NSCLC for which prior standard first-line treatment containing an anti-programmed cell death protein 1/programmed cell death protein 1 ligand (PD-1/PD-L1) checkpoint inhibitor (CPI) alone or in combination has failed and that has progressed on no more than 1 prior systemic therapy. In Phase 2, participants with nonsquamous NSCLC must have not received more than 1 prior systemic therapy and must not have presented with disease progression during the first 6 months of treatment with first-line CPI/anti-PD-(1/L1)-containing therapy. Note: In Phase 1, participants with nonsquamous NSCLC and known driver mutations/genomic aberrations (e.g., epidermal growth factor receptor (EGFR), B-Raf proto-oncogene mutation V600E [BRAF V600E], and ROS proto-oncogene 1 [ROS1] sensitizing mutations, neurotrophic receptor tyrosine kinase [NRTK] gene fusions, and anaplastic lymphoma kinase [ALK] rearrangements) must have also shown progressive disease after treatment with a commercially available targeted therapy. In Phase 2, participants with driver mutations are not eligible. B. CPI-naive cervical cancer (squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix) participants for whom prior standard first-line treatment has failed and who have received no more than 1 prior systemic line of therapy for recurrent or Stage IVB cervical cancer. Note: The following cervical tumors are not eligible: minimal deviation/adenoma malignum, gastric-type adenocarcinoma, clear-cell carcinoma, and mesonephric carcinoma. Histologic confirmation of the original primary tumor is required via pathology report. Note: First-line treatment must have consisted of platinum-containing doublet. Chemotherapy administered concurrently with primary radiation (e.g., weekly cisplatin) is not counted as a systemic chemotherapy regimen. C. CPI-naïve microsatellite stable-colorectal cancer (MSS-CRC) participants for whom prior standard first-line treatment has failed and who have progressed on no more than 3 chemotherapy regimens. Note: Participants must have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing regimens if indicated. D. Unresectable Stage III or Stage IV cutaneous melanoma that has not received prior therapy in the metastatic setting. Note: Participants with acral melanoma are not eligible. Participants who have presented with disease relapse after =6 months of the last dose of CPI or BRAF-mitogen-activated protein kinase kinase (MEK) inhibitor in the adjuvant setting are eligible. E. Squamous NSCLC for which prior standard first-line treatment containing an anti-PD-(1/L1) checkpoint inhibitor alone or in combination has failed. Participant must have not received more than 1 prior systemic therapy and must not have presented with disease progression during the first 6 months of treatment with first-line CPI/anti-PD-(1/L1)-containing therapy. F. Squamous or nonsquamous NSCLC for which prior standard first-line treatment containing an anti-PD-(1/L1) checkpoint inhibitor alone or in combination has failed within 6 months from the initiation of the CPI. Participants must not have received more than 1 prior systemic therapy in the metastatic setting. Note: Participants with driver mutations are not eligible.

2. Has at least 1 radiologically measurable lesion based on RECIST, Version 1.1. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

3. Has a performance status of 0 or 1 on the Eastern Cooperative Group Oncology (ECOG) Performance Scale.

4. Has left ventricular ejection fraction (LVEF) =40%; as measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan.

5. Has recovered to Grade 1 or baseline from all toxicity associated with previous therapy or have the toxicity established as sequela. Note: Has a neuropathy =Grade 2, any grade alopecia, or autoimmune endocrinopathies with stable replacement therapy are permitted.

6. Demonstrate adequate organ function as described below:

A. Platelet count =75.0 × 10^9/L. B. Absolute neutrophil count (ANC) =1.0 × 10^9/L. C. Hemoglobin =85 g/L (red blood cell [RBC] transfusion allowed =14 days before assessment). D. Calculated creatinine clearance =30 mL/min using the Cockcroft-Gault formula. E. Aspartate aminotransferase (AST, GOT) and alanine aminotransferase (ALT, GPT) =3.0 times the upper limit of normal (ULN), <5.0 times the ULN if liver enzyme elevations are due to liver metastases; bilirubin =1.5 times the ULN. Participants with Gilbert's syndrome may have a bilirubin level >1.5 times the ULN, per discussion between the investigator and the medical monitor.

Exclusion Criteria:

1. History of uncontrolled brain metastasis (evidence of progression by imaging over a period of 4 weeks and/or neurologic symptoms that have not returned to baseline). Participant with treated brain metastases are allowed provided they are radiologically stable, without evidence of progression for at least 4 weeks by repeat imaging, clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment. Note: For asymptomatic participants, screening brain imaging is not required.

2. Second malignancy within the previous 3 years, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, cervical carcinoma in situ, resected colorectal adenomatous polyps, breast cancer in situ, or other malignancy for which the participant is not on active anticancer therapy.

3. Major surgery =14 days from the first dose of study drug and not recovered fully from any complications from surgery.

4. History of immune-related AEs related to treatment with immune CPIs that required treatment discontinuation.

5. Receiving or requires the continued use of medications that are known to be strong or moderate inhibitors and inducers of cytochrome P-450 (CYP) 3A4/5 and strong P-glycoprotein (Pgp) inhibitors.

6. Baseline prolongation of the QT interval corrected using Fridericia's formula (QTcF) (e.g., repeated demonstration of QTcF interval >480 milliseconds (ms), history of congenital long QT syndrome, or torsades de pointes).

7. Has a history of autoimmune disease requiring systemic immunosuppressive therapy with daily doses of prednisone >10 mg/day or equivalent doses, or any other form of immunosuppressive therapy. Hormone replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for thyroid, adrenal or pituitary insufficiency) for endocrinopathies are not considered prohibited forms of systemic treatment of an autoimmune disease.

8. Has a history of noninfectious pneumonitis that required steroids or a history of interstitial lung disease.

9. Has an evidence of active, non-infectious pneumonitis.

10. Has a history of allogeneic tissue or solid organ transplant.

11. Has an active infection requiring systemic therapy.

12. Has a known history of human immunodeficiency virus (HIV) infection or any other relevant congenital or acquired immunodeficiency.

13. Has a known hepatitis B virus surface antigen seropositive or detectable hepatitis C infection viral load. Note: Participants who have positive hepatitis B core antibody or hepatitis B surface antigen antibody can be enrolled but must have an undetectable hepatitis B viral load.

14. History of any of the following =6 months before first dose: congestive heart failure New York Heart Association Grade III or IV, unstable angina, myocardial infarction, unstable symptomatic ischemic heart disease, uncontrolled hypertension despite appropriate medical therapy, ongoing symptomatic cardiac arrhythmias >Grade 2, pulmonary embolism or symptomatic cerebrovascular events, or any other serious cardiac condition (e.g., pericardial effusion or restrictive cardiomyopathy). Chronic atrial fibrillation on stable anticoagulant therapy is allowed.

15. Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of AEs or has compromised ability to provide written informed consent.

Related Conditions & MeSH terms

• Advanced or Metastatic Solid Tumors
• Neoplasms

Intervention

Drug:
• TAK-981
TAK-981 IV infusion.
• Pembrolizumab
Pembrolizumab IV infusion.

Locations

Country	Name	City	State
Brazil	Fundacao Pio XII Hospital de Cancer de Barretos	Barretos	Sao Paulo
Brazil	Cetus Hospital Dia Oncologia	Belo Horizonte
Brazil	Instituto de Oncologia Do Parana	Curitiba	Parana
Brazil	ONCOSITE Centro de Pesquisa Clinica Em Oncologia	Ijui	Rio Grande Do Sul
Brazil	Hospital de Clinicas de Porto Alegre (HCPA) - PPDS	Porto Alegre	Rio Grande Do Sul
Brazil	Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)	Porto Alegre	Rio Grande Do Sul
Brazil	INCA Instituto Nacional de Cancer	Rio De Janeiro
Brazil	Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira	Rio de Janeiro
Brazil	Hospital de Base Da Faculdade de Medicina de Sao Jose Do Rio Preto	Sao Jose Do Rio Preto	Sao Paulo
China	Sun Yat-Sen University Cancer Center	Guangzhou	Guangdong
China	The First Affiliated Hospital, Zhejiang University School of Medicine - PPDS	Hangzhou	Zhejiang
China	Union Hospital Tongji Medical College Huazhong University of Science and Technology	Wuhan	Hubei
Croatia	Clinical Hospital Centre Osijek	Osijek
Croatia	General Hospital Pula	Pula
Croatia	University Hospital Centre Split	Split
Croatia	Klinicki bolnicki centar Zagreb	Zagreb	Grad Zagreb
Japan	National Cancer Center Hospital	Chuo-Ku	Tokyo
Japan	The Cancer Institute Hospital of Japanese Foundation For Cancer Research	Chuo-Ku	Tokyo
Japan	National Cancer Center East	Kashiwa-Shi	Tiba
Latvia	Pauls Stradins Clinical University Hospital	Riga
Latvia	Riga East Clinical University Hospital Latvian Oncology Center	Riga
Lithuania	Hospital of Lithuanian University of Health Sciences Kaunas Clinics	Kaunas	Kauno Apskritis
Lithuania	Hospital of Lithuanian University of Health Sciences Kauno klinikos	Kaunas	Kauno Apskritis
Lithuania	National Cancer Institute	Vilnius	Vilniaus Apskritis
Poland	Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy	Bydgoszcz
Poland	Uniwersyteckie Centrum Kliniczne-Ul. Smoluchowskiego 17	Gdansk	Pomorskie
Poland	Centrum Terapii Wspolczesnej	Lodz	Lodzkie
Poland	Instytut Medyczny Santa Familia Sp. z o. o.	Lodz
Poland	Specjalistyczna Praktyka Lekarska Slawomir Mandziuk	Lublin
Poland	Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie	Olsztyn
Poland	Med-Polonia Sp. z o.o.	Poznan
Switzerland	Universitaetsspital Bern - Inselspital	Bern
Switzerland	Kantonsspital Muensterlingen	Munsterlingen	Thurgau (de)
Switzerland	Kantonsspital Winterthur	Winterthur	Zurich (de)
United States	Georgia Cancer Center at Augusta University	Augusta	Georgia
United States	The Center for Cancer and Blood Disorders - PPDS	Bethesda	Maryland
United States	Montefiore Einstein Cancer Center - BRANY - PPDS	Bronx	New York
United States	University of North Carolina at Chapel Hill	Chapel Hill	North Carolina
United States	University of Virginia Health System	Charlottesville	Virginia
United States	University of Texas Southwestern Medical Center	Dallas	Texas
United States	Virginia Cancer Specialists (Fairfax) - USOR	Fairfax	Virginia
United States	Morristown Medical Center	Morristown	New Jersey
United States	Cancer Institute of New Jersey	New Brunswick	New Jersey
United States	Yale Cancer Center	New Haven	Connecticut
United States	University of Oklahoma Peggy and Charles Stephenson Cancer Center	Oklahoma City	Oklahoma
United States	University of California Irvine Medical Center	Orange	California
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania
United States	UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania
United States	Providence Cancer Institute, Franz Clinic	Portland	Oregon
United States	START South Texas Accelerated Research Therapeutics	San Antonio	Texas
United States	HonorHealth	Scottsdale	Arizona
United States	Stanford Cancer Institute (SCI)	Stanford	California

Sponsors (2)

Lead Sponsor	Collaborator
Takeda	Takeda Development Center Americas, Inc.

Countries where clinical trial is conducted

United States,  Brazil,  China,  Croatia,  Japan,  Latvia,  Lithuania,  Poland,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs)	An adverse event (AE) is any untoward medical occurrence in a participant administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. A TEAE is defined as an AE that occurs after administration of first dose of study drug and through 30 days after last dose of study drug or until start of subsequent antineoplastic therapy. AEs will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0 except cytokine release syndrome (CRS), will be graded according to American society for transplantation and cellular therapy (ASCST) Consensus Grading for CRS.	Up to 48 months
Primary	Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)	DLTs will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0 except cytokine release syndrome (CRS), will be graded according to American society for transplantation and cellular therapy (ASCST) Consensus Grading for CRS.	Up to Cycle 1 (each cycle is of 21 days)
Primary	Phase 1: Number of Participants With Grade 3 or Higher Treatment Emergent Adverse Events (TEAEs)		Up to 48 months
Primary	Phase 1: Number of Participants With One or More Serious Adverse Events (SAEs)	An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.	Up to 48 months
Primary	Phase 1: Number of Participants with One or More TEAEs Leading to Dose Modifications and Treatment Discontinuation		Up to 48 months
Primary	Phase 1: Number of Participants With Clinically Significant Laboratory Values	Laboratory parameters includes parameters of clinical chemistry, hematology, and urinalysis.	Up to 48 months
Primary	Phase 2: Overall Response Rate (ORR) as Assessed by the Investigator According to RECIST, Version 1.1	ORR is defined as the percentage of participants who achieve Complete Response (CR) and Partial Response (PR) (determined by the investigator) during the study according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.	Up to 60 months
Secondary	Phase 1: Cmax: Maximum Observed Plasma Concentration for TAK-981		Cycle 1 (each cycle is 21 days) Days 1 and 8 pre-dose and at multiple timepoints (Up to 24 hours); Days 4 and 11: at the end of infusion; Cycle 2, Days 1 and 8, at the end of infusion and at 2 hours post-dose
Secondary	Phase 1: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-981		Cycle 1 (each cycle is 21 days) Days 1 and 8 pre-dose and at multiple timepoints (Up to 24 hours); Days 4 and 11: at the end of infusion; Cycle 2, Days 1 and 8, at the end of infusion and at 2 hours post-dose
Secondary	Phase 1: AUCt: Area Under the Plasma Concentration-time Curve from Time 0 to Time t Over the Dosing Interval for TAK-981		Cycle 1 (each cycle is 21 days) Days 1 and 8 pre-dose and at multiple timepoints (Up to 24 hours); Days 4 and 11: at the end of infusion; Cycle 2, Days 1 and 8, at the end of infusion and at 2 hours post-dose
Secondary	Phase 1: AUC8: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for TAK-981		Cycle 1 (each cycle is 21 days) Days 1 and 8 pre-dose and at multiple timepoints (Up to 24 hours); Days 4 and 11: at the end of infusion; Cycle 2, Days 1 and 8, at the end of infusion and at 2 hours post-dose
Secondary	Phase 1: t1/2z: Terminal Disposition Phase Half-life for TAK-981		Cycle 1 (each cycle is 21 days) Days 1 and 8 pre-dose and at multiple timepoints (Up to 24 hours); Days 4 and 11: at the end of infusion; Cycle 2, Days 1 and 8, at the end of infusion and at 2 hours post-dose
Secondary	Phase 1: CL: Total Clearance After Intravenous Administration for TAK-981		Cycle 1 (each cycle is 21 days) Days 1 and 8 pre-dose and at multiple timepoints (Up to 24 hours); Days 4 and 11: at the end of infusion; Cycle 2, Days 1 and 8, at the end of infusion and at 2 hours post-dose
Secondary	Phase 1: Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-981		Cycle 1 (each cycle is 21 days) Days 1 and 8 pre-dose and at multiple timepoints (Up to 24 hours); Days 4 and 11: at the end of infusion; Cycle 2, Days 1 and 8, at the end of infusion and at 2 hours post-dose
Secondary	Phases 1 and 2: ORR as Defined by the Investigator According to Modified RECIST, Version 1.1 for Immune-Based Therapeutics (iRECIST) Modification		Up to 60 months
Secondary	Phases 1 and 2: Disease Control Rate (DCR)	DCR is defined as the percentage of participants who achieve stable disease (SD) or better (CR+PR+SD determined by the investigator) during the study.	Up to 60 months
Secondary	Phases 1 and 2: Durable Response Rate (DRR)	DRR is defined as the rate of objective responses (CR + PR) maintained for at least 6 months initiating at any time within 12 months of commencing therapy.	Up to 60 months
Secondary	Phases 1 and 2: Duration of Response (DOR)	DOR is defined as a time from the time of first documentation of tumor response to the first recorded occurrence of disease progression (PD) or death from any cause (whichever occurs first), through end of study (up to approximately 60 months).	Up to 60 months
Secondary	Phases 1 and 2: Progression-free Survival (PFS)	PFS is defined as time from the date of the first dose administration to the date of first documentation of PD or death due to any cause whichever occurs first, through the end of the study (up to approximately 60 months).	Up to 60 months
Secondary	Phases 1 and 2: Time to Response (TTR)	TTR is defined as time from the date of the first dose administration to the date of first documented PR or better (up to approximately 60 months).	Up to 60 months
Secondary	Phases 1 and 2: Time to Progression (TTP)	TTP is defined as the from the date of the first dose administration to the date of the first documentation of PD as defined by standard disease criteria.	Up to 60 months
Secondary	Phase 2: Overall Survival (OS)	OS is defined as the time from the date of the first dose administration to the date of death. Participants without documentation of death at the time of analysis will be censored at the date last known to be alive.	Up to 60 months
Secondary	Phase 1: Percentage of Participants at Each Dose Level Demonstrating Adduct Formation in Blood	TAK-981-small ubiquitin-like modifier (SUMO) adduct formation in blood will be evaluated.	Up to 48 months
Secondary	Phase 1: Percent Change in Small Ubiquitin-like Modifier (SUMO) 2/3 Signal With Pre and Post-dose in Blood	SUMO pathway inhibition in blood will be evaluated.	Up to 48 months
Secondary	Phase 2: Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs)		Up to 60 months
Secondary	Phase 2: Number of Participants With Grade 3 or Higher Treatment Emergent Adverse Events (TEAEs)		Up to 60 months
Secondary	Phase 2: Number of Participants with One or More TEAEs Leading to Dose Modifications and Treatment Discontinuation		Up to 60 months

External Links

•   To obtain more information about this study, click this link.